RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

Robert F. Kennedy Jr., who heads the Department of Health and Human Services, appointed individuals with financial interests in peptide companies to an FDA advisory panel, according to FDA records reviewed by The Washington Post. FDA scientists have raised concerns about peptide drugs, stating they lack sufficient testing and safety data. The appointments occurred as the agency considers policies on peptide accessibility. Kennedy's office did not respond to requests for comment on the panel selections.

Next story